Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24656674 | 0.74 | SCN5A (0.50) | MAPK14SCN5AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL21941232 | 0.73 | KDM4E (0.46) | KDM4EALDH1A1SMN1; SMN2CYP2C9HSD17B10 | |
| SCHEMBL19861782 | 0.72 | KDM4E (0.50) | MAPK14SCN5AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18912020 | 0.70 | KDM4E (0.49) | KDM4EALDH1A1SMN1; SMN2CYP2C9HSD17B10 | |
| SCHEMBL10224281 | 0.66 | KDM4E (0.50) | MAPK14SCN5AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15979322 | 0.64 | KDM4E (0.49) | KDM4EALDH1A1SMN1; SMN2CYP2C9HSD17B10 | |
| SCHEMBL21893827 | 0.64 | SCN5A (0.50) | MAPK14SCN5AKDM4EALDH1A1CYP1A2 | |
| SCHEMBL750920 | 0.63 | KDM4E (0.50) | SCN5AKDM4EALDH1A1CYP1A2SMN1; SMN2 | |
| SCHEMBL21237806 | 0.63 | KDM4E (0.50) | KDM4EALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL19292586 | 0.62 | ALDH1A1 (0.45) | MAPK14SCN5AKDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MAPK14 4428/4885SCN5A 1883/4885KDM4E 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.